ALKS logo

ALKS
Alkermes plc

2,179
Mkt Cap
$5.91B
Volume
3.08M
52W High
$36.60
52W Low
$25.17
PE Ratio
39.43
ALKS Fundamentals
Price
$38.27
Prev Close
$35.47
Open
$36.05
50D MA
$31.86
Beta
0.65
Avg. Volume
1.99M
EPS (Annual)
$1.43
P/B
3.37
Rev/Employee
$719,950.73
$3,472.01
Loading...
Loading...
News
all
press releases
Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles
Alkermes shares climbed after phase 3 LUMRYZ data met key endpoints in idiopathic hypersomnia as analysts raised price targets.read more...
Benzinga·1h ago
News Placeholder
More News
News Placeholder
Alkermes Announces Positive Topline Results From REVITALYZ Phase 3 Study Evaluating LUMRYZ (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the REVITALYZ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the investigational use of LUMRYZ (sodium oxybate) extended-release oral suspension in adults with idiopathic...
Business Wire·9h ago
News Placeholder
Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results
Alkermes reports positive Q1 results, beating expectations. Raises EPS guidance and maintains sales guidance. Analysts raise price targets.read more...
Benzinga·6d ago
News Placeholder
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises
ALKS beats Q1 estimates as strong proprietary drug sales lift revenues by 28%, sending shares higher, while Lumryz adds a fresh growth driver.
Zacks·6d ago
News Placeholder
Alkermes (NASDAQ:ALKS) Price Target Raised to $44.00 at Wells Fargo & Company
Wells Fargo & Company boosted their price target on shares of Alkermes from $43.00 to $44.00 and gave the company an "overweight" rating in a report on Wednesday...
MarketBeat·6d ago
News Placeholder
Alkermes (NASDAQ:ALKS) Price Target Raised to $50.00 at Needham & Company LLC
Needham & Company LLC increased their target price on Alkermes from $45.00 to $50.00 and gave the company a 'buy' rating in a research note on Wednesday...
MarketBeat·6d ago
News Placeholder
Alkermes (NASDAQ:ALKS) Reaches New 12-Month High - Time to Buy?
Alkermes (NASDAQ:ALKS) Reaches New 52-Week High - Time to Buy...
MarketBeat·7d ago
News Placeholder
Alkermes (ALKS) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·7d ago
News Placeholder
Alkermes Q1 Earnings Call Highlights
Alkermes (NASDAQ:ALKS) executives highlighted a strong start to 2026 and the completion of the Avadel Pharmaceuticals acquisition during the company's first-quarter earnings call, pointing to...
MarketBeat·7d ago
News Placeholder
Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·7d ago
<
1
2
...
>

Latest ALKS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.